Actively Recruiting
Phase III Study of Multivirus-Specific T-Cell Therapy for Treating Chemo-Resistant Viral Infections After Allogeneic Stem Cell Transplantation
Led by Tobias Feuchtinger · Updated on 2025-07-18
149
Participants Needed
33
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
The trial investigates the use of multivirus-specific T-cell transfer to treat children and adults who have undergone allogeneic stem cell transplantation HSCT and suffer from new or reactivated infections caused by Cytomegalovirus CMV, Epstein-Barr virus EBV, or Adenovirus AdV. These viral infections are significant complications after HSCT due to the weakened immune system from the transplantation and its preparative treatments. The study aims to confirm the effectiveness of this treatment in restoring protective T-cell immunity against these infections. Participants will be randomly assigned in a 21 ratio to receive either a single infusion of multivirus-specific T cells or a placebo. The T cells are prepared to target the three viruses CMV, EBV, and AdV, with dosing based on donor matching and recipient body weight. The study begins with a screening visit, followed by treatment within 28 days. Patients will be monitored on the day of infusion and at multiple intervals up to 15 weeks after treatment. Throughout the study, participants will undergo assessments including viral load measurements, symptom evaluation, quality of life questionnaires, and immune monitoring through blood samples. Researchers will track viral clearance, disease progression, graft-versus-host disease GvHD, toxicity, and overall survival. Safety and treatment effects will be closely monitored during the follow-up visits, which extend up to 15 weeks post-treatment.
CONDITIONS
Brief Title
Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections
Research Team
T
Tobias Feuchtinger, Prof
T
Theresa Käuferle, Dr
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here